Side-Effects following Oxford/AstraZeneca COVID-19 Vaccine in Tororo District, Eastern Uganda: A Cross-Sectional Study

Jagire Onyango, David Mukunya (), Agnes Napyo, Ritah Nantale, Brian T. Makoko, Joseph K. B. Matovu, Benon Wanume, David Okia, Francis Okello, Sam Okware, Peter Olupot-Olupot and Yovani Lubaale
Additional contact information
Jagire Onyango: Department of Community and Public Health, Busitema University, Mbale P.O. Box 236, Uganda
David Mukunya: Department of Community and Public Health, Busitema University, Mbale P.O. Box 236, Uganda
Agnes Napyo: Department of Community and Public Health, Busitema University, Mbale P.O. Box 236, Uganda
Ritah Nantale: Department of Nursing, Busitema University, Mbale P.O. Box 236, Uganda
Brian T. Makoko: Department of Community and Public Health, Busitema University, Mbale P.O. Box 236, Uganda
Joseph K. B. Matovu: Department of Community and Public Health, Busitema University, Mbale P.O. Box 236, Uganda
Benon Wanume: Department of Community and Public Health, Busitema University, Mbale P.O. Box 236, Uganda
David Okia: Department of Community and Public Health, Busitema University, Mbale P.O. Box 236, Uganda
Francis Okello: Department of Community and Public Health, Busitema University, Mbale P.O. Box 236, Uganda
Sam Okware: Department of Research, Uganda National Health Research Organizations, Kampala P.O. Box 465, Uganda
Peter Olupot-Olupot: Department of Community and Public Health, Busitema University, Mbale P.O. Box 236, Uganda
Yovani Lubaale: Department of Community and Public Health, Busitema University, Mbale P.O. Box 236, Uganda

IJERPH, 2022, vol. 19, issue 22, 1-10

Abstract: Effective, safe and proven vaccines would be the most effective strategy against the COVID-19 pandemic but have faced rollout challenges partly due to fear of potential side-effects. We assessed the prevalence, profiles, and predictors of Oxford/AstraZeneca vaccine side-effects in Tororo district of Eastern Uganda. We conducted telephone interviews with 2204 participants between October 2021 and January 2022. Multivariable logistic regression was conducted to assess factors associated with Oxford/AstraZeneca vaccine side-effects using Stata version 15.0. A total of 603/2204 (27.4%) of the participants experienced one or more side-effects (local, systemic, allergic, and other side-effects). Of these, 253/603 (42.0%) experienced local side-effects, 449/603 (74.5%) experienced systemic side-effects, 11/603 (1.8%) experienced allergic reactions, and 166/603 (27.5%) experienced other side-effects. Ten participants declined to receive the second dose because of side-effects they had experienced after the first dose. Previous infection with COVID-19 (adjusted odds ratio (AOR): 4.3, 95% confidence interval (95% CI): 2.7–7.0), being female (AOR: 1.3, 95% CI: 1.1–1.6) and being a security officer (AOR: 0.4, 95% CI: 0.2–0.6) were associated with side-effects to the Oxford/AstraZeneca vaccine. We recommend campaigns to disseminate correct information about potential side-effects of the Oxford/AstraZeneca vaccine and strengthen surveillance for adverse events following vaccination.

Keywords: side-effects; COVID-19; Oxford/AstraZeneca vaccine; Uganda (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/22/15303/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/22/15303/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:22:p:15303-:d:977842

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().